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AbSTRACT
background: The ACCEPT registry was designed with the 
purpose of identifying the incorporation of evidence in the 
treatment of acute coronary syndrome. The objective of this 
analysis is to describe the antithrombotic therapy adopted in 
the treatment of patients undergoing primary percutaneous 
coronary intervention (PCI) in centers participating in this 
national project. Methods: We evaluated the subgroup of 
patients undergoing primary PCI, measuring variables related 
to demographic characteristics as well as the prescription of 
evidence-based interventions, focusing on in-hospital and 
6- month antithrombotic therapy. Results: From August 2010 
to December 2011, 588 patients with mean age of 61.8 
± 12.3 years were studied, 75.2% were males and 24.1% 
had diabetes mellitus. The dual antiplatelet therapy most 
commonly given was the combination of acetylsalicylic 
acid (ASA) and clopidogrel. Unfractionated heparin and 
enoxaparin were the predominant anticoagulation therapy 
during and after the procedure, respectively. When com-
pared to in-hospital prescription, a significant decrease 
in the rate of patients using ASA (98.3% vs 93.9%; P < 
0.0001) and clopidogrel (95.4% vs 67.7%; P < 0.0001) 
was observed at the 6-month follow-up. Conclusions: 
In the ACCEPT registry, a high percentage of in hospital 
prescription of dual antiplatelet therapy was observed in 
patients undergoing primary PCI, notably the combination 
of ASA and clopidogrel, with an inadvertent reduction of 
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RESUMO
Farmacoterapia Antitrombótica Intra-Hospitalar  
e aos Seis Meses após Intervenção Coronária 
Percutânea Primária: Análise do Registro da Prática 
Clínica em Síndrome Coronária Aguda (ACCEPT)
Introdução: O registro ACCEPT foi idealizado com o propósito 
de identificar a incorporação de evidências no tratamento da 
síndrome coronária aguda. O objetivo da presente análise é 
descrever a terapia antitrombótica adotada no tratamento de 
pacientes submetidos a intervenção coronária percutânea (ICP) 
primária em centros participantes desse projeto nacional. Mé-
todos: Avaliamos o subgrupo de pacientes submetidos a ICP 
primária, aferindo as variáveis relacionadas às características 
demográficas bem como à prescrição de intervenções baseadas 
em evidências, com enfoque na farmacoterapia antitrombótica 
hospitalar e aos 6 meses de seguimento. Resultados: No 
período de agosto de 2010 a dezembro de 2011 foram avalia-
dos 588 pacientes com média de idade de 61,8 ± 12,3 anos, 
75,2% pertencentes ao sexo masculino e 24,1% portadores 
de diabetes melito. A terapia antiplaquetária dupla mais co-
mumente administrada foi a associação ácido acetilsalicílico 
(AAS) e clopidogrel. Heparina não-fracionada e enoxaparina 
foram a terapêutica anticoagulante predominante durante e 
após o término do procedimento, respectivamente. Compara-
tivamente à prescrição na fase intra-hospitalar, constatou-se, 
aos 6 meses de seguimento, queda significativa da taxa de 
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clopidogrel at the 6- month follow -up, encouraging efforts 
to use evidence -based practices.
 
 
 
 
 
 
DESCRIPTORS: Myocardial infarction. Angioplasty. Registry. 
Platelet  aggregation  inhibitors.
semester of 2010, and with the start of patient data 
collection in August of the same year. A total of 2,608 
patients enrolled until December 2011, corresponding to 
Phase I of the project, were analysed through comple-
tion of the dedicated electronic form (at admission, 30 
days, and 180 days). For this purpose, 47 researching 
centers were organized, seeking to cover the greatest 
possible territorial extension, representing all regions 
of the Brazilian states, including hospitals with public 
assistance (Brazilian Unified Health System), health 
insurance companies, and private centers.
These centers were assembled using two criteria: 
an invitation was sent to institutions that had already 
been considered eligible, and an active search for new 
centers was conducted through the promotion of the 
opportunity to participate at the electronic portal of 
the SBC. The criteria for participation were evidence 
of available research ethics committee and the capa c ity 
to follow-up patients for up to one year, as well as 
the existence of patients who met the clinical scope 
of this registry.
All centers received training regarding the study 
protocol and electronic system, in person or by phone, 
supported by the coordination team. The quality control 
of study data was verified through several strategies, 
such as the use of a dedicated electronic form for 
collection of clinical variables, centralized verification 
of the collected variables, in-person monitoring of the 
five centers with larger numbers of recruited patients, 
and random selection of 20% of centers for in-person 
monitoring. The protocol was approved by the re-
search ethics committee of the Hospital do Coração 
(São Paulo, SP, Brazil) and, subsequently, the study 
protocol was approved by the local committee of each 
participating center.
All patients signed the informed consent, and the 
study was performed in accordance with the principles 
of the current version of the Declaration of Helsinki, of 
the Good Clinical Practice Guidelines, and of Resolu-
tion 196/96 of the Brazilian National Health Council.
This study analysed STEMI patients undergoing 
primary PCI, assessing the variables related to the 
demographic characteristics, as well as the prescrip-
tion of evidence-based interventions, with a focus 
pacientes em uso de AAS (98,3% vs. 93,9%; P < 0,0001) e 
clopidogrel (95,4% vs. 67,7%; P < 0,0001). Conclusões: No 
registro ACCEPT, elevado porcentual de prescrição hospitalar 
de terapia antiplaquetária dupla foi observado em pacientes 
submetidos a ICP primária, notadamente da associação AAS 
e clopidogrel, com redução inadvertida do último aos 6 me-
ses de seguimento, motivando esforços para adequação das 
práticas fundamentadas por evidências.
DESCRITORES: Infarto do miocárdio. Angioplastia. Registro. 
Inibidores da agregação de plaquetas.
E arly coronary reperfusion, whether mechanical or chemical, and antithrombotic therapy are important steps in the care of patients with acute myocardial 
infarction with ST-segment elevation (STEMI), known to 
be effective in reducing morbidity and mortality. Over 
the past 15 years, several randomized clinical trials, 
meta-analyses, and registries corroborated the positive 
impact of new reperfusion strategies and adjunctive 
drug therapy in this scenario, with subsequent incorpo-
ration into reviews of guidelines that direct cardiology 
practice.1-3
Observational analysis of the Can Rapid Risk Strati-
fication of Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the ACC/AHA 
Guidelines (CRUSADE) registry, encompassing 64,775 
patients admitted to 350 institutions in the United 
States, found that every 10% increase in adherence 
to therapies with a class I degree of recommendation 
according to the guidelines brought a similar reduction 
of 10% in the in-hospital mortality risk.4 These findings 
can be translated to patients with STEMI, as shown in 
a Swedish registry involving 61,238 patients, which 
observed, over 12 years, that the increased adoption 
of evidence-based therapies promoted significant and 
sustained reduction in mortality.5
In Brazil, there is little information documenting 
clinical practice in patients with acute coronary syn-
drome at the national level. The Acute Coronary Care 
Evaluation of Practice (ACCEPT) registry was designed 
with the purpose of identifying the incorporation of 
evidence to the treatment of this disease.6 The goal 
of the present study is to describe the antithrombotic 
therapy used in the treatment of patients undergoing 
primary percutaneous coronary intervention (PCI), during 
the in-hospital phase and at six months of follow-up, 
in the centers participating in this national project.
Methods
The rationale, methodology, organization, and 
ACCEPT registry committees have all been previously 
detailed.6,7 In summary, it is a prospective, voluntary, 
multicenter study, designed and managed by the Bra-
zilian Society of Cardiology (Sociedade Brasileira de 
Cardiologia – SBC), logistically structured in the first 
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on antithrombotic drug therapy. Clinical outcomes 
analysed in this study were cardiovascular mortality, 
acute myocardial infarction, stroke, and severe bleed -
ing. The occurrence of the above mentioned clinical 
outcomes was verified at admission and after 180 days. 
In accordance with the classification of the Bleeding 
Academic Research Consortium,8 severe bleeding 
was defined as type 3 (3a, bleeding with a decrease 
in hemoglobin ≥  3  g/dL and <  5  g/dL or packed red 
blood cell transfusion; 3b, bleeding with a decrease 
in hemoglobin ≥  5  g/dL, or cardiac tamponade or 
bleeding requiring surgical intervention, or bleeding 
requiring intravenous vasoactive drugs; and 3c, in-
tracranial hemorrhage, or subcategories confirmed by 
autopsy, imaging assessment or lumbar puncture, or 
intraocular bleeding with vision impairment) or type 5 
(5a, likely fatal bleeding; 5b definitive fatal bleeding).
This registry is owned by SBC, using its own 
financial resources dedicated to this purpose and its 
implementation. The Instituto de Ensino e Pesquisa do 
Hospital do Coração (IEP/HCor – São Paulo, SP, Brazil) 
was employed to operationalize this registry, under the 
coordination of SBC.
statistical Analysis
Continuous variables were described as means and 
standard deviations, and categorical variables as absolute 
and relative frequencies. Proportions were compared 
between two independent groups using Fisher’s exact 
test. The SAS (Statistical Analysis System – Cary, USA) 
software, version 9.3, was used for statistical analysis. 
p-values < 0.05 (two-tailed) were considered statisti-
cally significant.
Results
From August 2010 to December 2011 2,608 patients 
were evaluated, concerning Phase I of the ACCEPT 
registry, of whom 640 were submitted to primary PCI. 
With a loss to follow-up at six months of 8.1% (52 
cases), the final analysis consisted of 588 patients whose 
baseline clinical and demographic characteristics are 
shown in Table 1. The mean age of patients was 61.8 
± 12.3 years, 75.2% were males, 24.1% had diabetes 
mellitus, and 20.6% had a history of acute myocardial 
infarction.
The percentage of normal epicardial flow (Thromb-
olysis in Myocardial Infarction [TIMI] 3) achieved at 
the end of the procedure with residual stenosis < 20% 
was high (> 96%). Stents were routinely used, with a 
predominance of bare-metal stents, whereas drug-eluting 
stents were used in 22.4% of the interventions. The 
approach was the predominantly femoral, corresponding 
to 69.7% of the cases (Table 2).
The most commonly administered dual antiplatelet 
therapy was the combination of acetylsalicylic acid 
(ASA) and clopidogrel. Unfractionated heparin and 
enoxaparin constituted the predominant anticoagulant 
therapy during and after the procedure, respectively 
(Table 3). Beta-blockers were prescribed to 76.7% of 
the patients, angiotensin-converting enzyme inhibitors 
or angiotensin receptor blockers to 68%, and statins 
to 89.5%. Compared to prescription at the in-hospital 
phase, it was observed that there was a significant de-
crease in the rate of patients using acetylsalicylic acid 
(98.3% vs. 93.9%; P < 0.0001) and clopidogrel (95.4% 
vs. 67.7%; P < 0.0001) at the six-month follow-up, 
with a small number proportion of patients using the 
new ADP P2Y12 receptor inhibitors, prasugrel (0.7% vs. 
0.3%) or ticagrelor (1.2% vs. 0.3%) (Figure 1).
Figure 2 illustrates the occurrence of adverse clinical 
outcomes at the end of 180 days, with a cumulative 
rate of combined events of 10.4%, mainly due to new 
Table 1 
baseline clinical and demographic characteristics
Variables n = 588
Age, years (mean ± SD) 61.8 ± 12.3
Male gender, n (%) 442 (75.2)
Systemic arterial hypertension, n (%) 395 (67.2)
Diabetes mellitus, n (%) 142 (24.1)
Dyslipidaemia, n (%) 278 (47.3)
Smoking, n (%) 185 (31.5)
Obesity, n (%) 187 (31.8)
Previous acute myocardial 
infarction, n (%)
121 (20.6)
Previous stroke, n (%) 47 (7.9)
Chronic renal failure, n (%) 17 (2.9)
Table 2  
Angiographic and procedural characteristics
Variables n = 588
Number of affected vessels, n (%)
One vessel 296 (50.3)
Two vessels 172 (29.3)
Three vessels 111 (18.9)
Non-obstructive atherosclerotic 
disease
9 (1.5)
Femoral access, n (%) 410 (69.7)
Radial access, n (%) 178 (30.3)
Stent implant, n (%) 562 (95.6)
Drug-eluting 126 (22.4)
Bare-metal 436 (77.6)
Procedural success, n (%) 568 (96.6)
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of dual antiplatelet therapy at six months, a reduction 
in their use was observed, particularly ADP inhibitors, 
indicating the need for a better implementation of the 
current guidelines, whose recommendation is to extend 
therapy for a period of 12 months, given the positive 
impact on patient prognosis of greater adherence to 
established evidence.2,3
Clopidogrel was administered to over 95% of the 
assessed population, which may be explained by the 
extensive experience with the drug, the decrease in 
cost after its patent expired, and the available generic 
formulations, making it easily accessible even in the 
public health system, after its incorporation to the 
Line of Care in Acute Myocardial Infarction of the 
Emergency Care Network of the Brazilian Ministry of 
Health. Furthermore, the new P2Y12 inhibitors, prasugrel 
and ticagrelor, became commercially available in Brazil 
in late 2010 and mid-2011, respectively. Considering 
that the obtained data reflect patients included in the 
registry between August 2010 and December 2011, 
this explains the low number of individuals using these 
new agents.
In fact, prasugrel and ticagrelor are first-line anti-
platelet drugs in the treatment of STEMI, since they 
have earlier action onset, and greater antiplatelet and 
anti-ischemic efficacy when compared to clopidogrel.9,10 
In the Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition – Thromb-
olysis in Myocardial Infarction 38 (TRITON-TIMI 38) 
study, prasugrel promoted a decrease in the primary 
composite outcome (cardiovascular death, myocardial 
infarction, and stroke) in patients undergoing primary 
PCI, consistent with the findings of the main analysis, 
but without a significant increase in the risk of major 
bleeding unrelated to CABG.11 In turn, in the Platelet 
Inhibition and Patient Outcomes (PLATO) study, the 
use of ticagrelor determined a decrease in reinfarction, 
total mortality, and definitive stent thrombosis, analysed 
separately, at the expense of an increased rate of stroke, 
without increasing the risk of severe bleeding.12
cases of myocardial infarction in 6.8% of the population.
discussion
The main findings regarding antithrombotic drug 
therapy used in patients with acute myocardial infarc-
tion undergoing primary PCI in the first phase of the 
ACCEPT registry are the high rate of in-hospital prescrip-
tion of dual antiplatelet therapy, primarily consisting 
of ASA and clopidogrel, restricted use of glycoprotein 
IIb/IIIa receptor inhibitors, and the choice of unfrac-
tionated heparin as the standard anticoagulant agent 
during the procedure. As a caveat to the prescription 
Table 3  
In-hospital antithrombotic therapy
Variables n = 588
Acetylsalicylic acid, n (%) 578 (98.3)
Clopidogrel, n (%) 561 (95.4)
Prasugrel, n (%) 4 (0.7)
Ticagrelor, n (%) 7 (1.2)
Glycoprotein IIb/IIIa receptor 
inhibitors, n (%)
114 (19.4)
Abciximab 59 (51.8)
Tirofiban 55 (48.2)
Intra-procedural unfractionated 
heparin, n (%)
514 (87.4)
Intra-procedural enoxaparin, n (%) 74 (12.6)
Post-procedural unfractionated 
heparin, n (%)
101 (17.2)
Post-procedural enoxaparin, n (%) 377 (64.1)
Post-procedural fondaparinux, n (%) 51 (5.3)
Figure 1 – Antiplatelet therapy in-hospital and at six months of follow-
up (* P < 0.0001).
Figure 2 – Adverse clinical events at 6 months of follow-up.
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Glycoprotein IIb/IIIa receptor inhibitors, whose ef-
ficacy was demonstrated in studies performed before 
the routine use of dual antiplatelet therapy, showed 
a decline in their prescription, compared to previous 
publications.13,14 The consolidation of oral dual anti-
platelet therapy, the constant search for the balance 
between anti-ischemic efficacy and safety, as well as 
the advent of ADP inhibitors with higher power justify 
this finding, whereas the use of parenteral agents are 
restricted to specific and rescue situations, such as 
large thrombotic burden, coronary flow disorders, and 
thrombotic complications.
As for the choice of anticoagulant administered 
during the procedure, considering the unavailability of 
new options, such as bivalirudin, unfractionated heparin 
remains the preferred agent. The former, not marketed 
in Brazil, showed a reduction of hospital mortality at 
30 days, with maintenance of the benefit at three years, 
when compared to the association of unfractionated 
heparin and glycoprotein IIb/IIIa inhibitors, a result 
attributed to the decrease in the occurrence of severe 
bleeding.15,16 The ACCEPT registry shows only a frac-
tion of patients treated with enoxaparin during primary 
PCI, a practice supported by the results of the Acute 
myocardial infarction treated with primary angioplasty 
and intravenous enoxaparin or unfractionated heparin 
to lower ischemic and bleeding events at short- and 
long-term follow-up (ATOLL) study. In this study, 
intravenous enoxaparin promoted a reduction of the 
main secondary composite outcome (death, recurrent 
acute coronary syndrome, or urgent revascularization), 
when compared to unfractionated heparin, with no 
difference in the primary composite outcome (death, 
acute myocardial infarction complication, procedural 
failure, or severe bleeding).17
Finally, the cardiovascular mortality rate of 2.6% 
at six months is close to rates obtained in randomized 
trials, characterized by patients with less severe clin-
ical profile, thus differing from the published results 
of similar large international registries.18,19 However, 
comparative analysis of the ACCEPT registry with other 
registries should be performed with caution, given its 
limitations: it is restricted to the reality of the partic-
ipating tertiary centers and their service profile; centers 
with less infrastructure and lacking a research ethics 
committee were excluded; patients were included in 
a voluntary and non-consecutive manner; and it had a 
limited number of patients when compared to similar 
international registries.
conclusions
The ACCEPT registry shows a high percentage of 
in-hospital prescription of dual antiplatelet therapy to 
patients with acute myocardial infarction undergoing 
primary PCI, notably the association of acetylsalicylic 
acid and clopidogrel, with an inadvertent decrease in 
the latter at six months of follow-up, which should 
encourage efforts to implement evidence-based prac-
tices. The decline in the use of glycoprotein IIb/IIIa 
inhibitors follows a collective trend, supported by 
guidelines, and unfractionated heparin, despite the 
passage of time, remains the preferred anticoagulant 
agent in Brazil.
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Porto Alegre (Porto Alegre, RS): Carisi Polanczyk (120); Santa 
Casa de Marília (Marília, SP): Pedro Beraldo de Andrade (88); 
Instituto Cardiopulmonar (Salvador, BA): Luiz Eduardo Ritt 
(73); Hospital de Terapia Intensiva (Teresina, PI): Paulo Márcio 
Sousa Nunes (60); Hospital Vera Cruz (Campinas, SP): Silvio 
Giopatto (58); Instituto de Cardiologia de Santa Catarina (São 
José, SC): Ilnei Pereira Filho (57); Hospital São Vicente (Passo 
Fundo, RS): Hugo Vargas Filho (56); Hospital São Paulo (São 
Paulo, SP): Antônio Carlos C. Carvalho (52); Santa Casa de 
Votuporanga (Votuporanga, SP): Mauro Esteves Hernandes (49); 
Hospital Madre Teresa (Belo Horizonte, MG): Roberto Luiz 
Marino (44); Sociedade Hospital Angelina Caron (Campina 
Grande do Sul, PR): Dalton Bertolim Precoma (43); Hospital 
Lifecenter (Belo Horizonte, MG): Estevão Lanna Figueiredo 
(43); Hospital do Coração do Cariri (Barbalha, CE): Francisco 
Carleial Feijó de Sá (42); Hospital do Coração de Poços de 
Caldas (Poços de Caldas, MG): Frederico Toledo Campos 
Dall’Orto (42); Hospital Santa Izabel (Salvador, BA): Gilson 
Soares Feitosa Filho (37); Hospital Santa Paula (São Paulo, SP): 
Otávio Celso Gebara (35); Hospital Regional do Mato Grosso 
do Sul (Campo Grande, MS): Christiano Pereira (35); Hospital 
Pró-Cardíaco (Rio de Janeiro, RJ): Luiz Antônio Almeida Campos 
(33); Hospital Universitário Francisca Mendes (Manaus, AM): 
Mariano Terrazas (31); Hospital Bandeirantes (São Paulo, SP): 
Hélio Castelo (30); Instituto Estadual de Cardiologia Aloysio de 
Castro (Rio de Janeiro, RJ): Roberto Bassan (30); Hospital do 
Coração do Brasil (Brasília, DF): Alberto Gomes Fonseca (29); 
Santa Casa de Porto Alegre (Porto Alegre, RS): Paulo Ernesto 
Leães (26); Hospital Santa Rita (Maringá, PR): Raul D’Aurea 
Mora Júnior (26); Centro Hospitalar Unimed (Joinville, SC): 
Rogério Carregoza Dantas (25); Hospital Sírio Libanês (São 
Paulo, SP): Roberto Kalil Filho (21); Hospital Universitário 
São Francisco (Bragança Paulista, SP): Murilo de Oliveira 
Antunes (20); Instituto de Moléstias Cardiovasculares (São 
José do Rio Preto, SP): Gilmar Valdir Greque (16); Hospital 
Estadual e Pronto-Socorro João Paulo II (Porto Velho, RO): 
Sérgio de Paulo Melo (15); Hospital Mãe de Deus (Porto 
Alegre, RS): Euler Manenti (11); Instituto de Cardiologia de 
Uruguaiana (Uruguaiana, RS): Sydnei Campodonico Filho (11); 
Real Hospital Português (Recife, PE): Sérgio Montenegro (9); 
Hospital Beneficência Portuguesa (São José do Rio Preto, SP): 
Gilmar Valdir Greque (7); Hospital da Cidade (Salvador, BA): 
Marcelo S. Teixeira (6); Hospital de Base da Sétima Região 
(Bauru, SP): Adriana F. Daher Berbel (5); Hospital Santa Izabel 
(Blumenau, SC): Sérgio L. Zimmermann (4); Instituto Nacional 
de Cardiologia (Rio de Janeiro, RJ): Marco Antônio de Mattos 
(4); Instituto do Coração do Triângulo Mineiro (Uberlândia, 
MG): Roberto Botelho (4); Hospital Prontocor (Rio de Janeiro, 
RJ): Paulo Henrique Godoy (3); and Instituto de Cardiologia 
do Distrito Federal (Brasília, DF): Núbia W. Vieira (2).
